AR and prostate carcinoma: We utilized the WTS data of 278 distinct patients with mCRPC, together with 49 hormone-sensitive prostate cancer tissues and 40 normal-adjacent prostate tissues, to inventory the expression of recurrent AR-Vs and generate a uniform compendium of AR-Vs in both hormone-sensitive and late-stage castration-resistant setting.